AtlasEdge Further Expands Coverage Across Europe with Acquisition of Twelve Data Centres from Colt Data Centre Services (DCS)
2.11.2021 12:00:00 EET | Business Wire | Press release
AtlasEdge, a pan-European edge data centre provider, has today announced the successful acquisition of twelve data centres. The deal is with Colt DCS, a world-class provider of Hyperscale data centres across Europe & APAC.
The successful acquisition from Colt strengthens AtlasEdge’s unique portfolio of distributed data centres that are positioned to support localised or low latency applications. AtlasEdge now operates more than 100 data centres across eleven countries in Europe, supporting more than 700 customers and providing connectivity to more than 50 different on-net carriers.
AtlasEdge provides a pan-European data centre portfolio that allows customers to design and configure their technology and network infrastructure to meet the growing requirements for lower latency, higher performance and localised solutions. With demand gravitating towards the edge of networks, AtlasEdge’s distributed and highly connected footprint provides a unique solution that is aligned with the next wave of growth in digital infrastructure.
This acquisition further expands AtlasEdge’s coverage and accelerates time to market in several new geographies, as well as establishing a collaboration between AtlasEdge and Colt Data Centre Services, with Colt Technology Services becoming an anchor tenant across multiple facilities. This network-neutral colocation strategy enables AtlasEdge’s customers to optimise their network routes, minimise their bandwidth costs and take advantage of the wide community of cloud, content, technology and enterprise companies present in the facilities.
The portfolio includes data centers in key tier one and tier two markets across Europe, including Amsterdam, Barcelona, Berlin, Brussels, Copenhagen, Hamburg, London, Madrid, Milan, Paris and Zurich.
“We are delighted to welcome these sites into our expanding portfolio,” commented Josh Joshi, Executive Chairman, AtlasEdge. “We are tapping into an exciting and emerging market where real time data traffic is growing and compute is gravitating to the edge of the network. As this demand builds, AtlasEdge is uniquely positioned to deliver seamless, localised and ultra-low latency digital infrastructure to our customers — from cloud providers to streaming services and enterprises. Our approach is open, carrier neutral and collaborative, and we look forward to working alongside Colt.”
Niclas Sanfridsson, CEO, Colt DCS, added, “Demand for data storage and cloud capabilities has never been higher, and so is the need for businesses to scale and find capacity. By restructuring and focusing on our hyperscale facilities, we can meet our customers’ needs on demand with true scalability and efficiency, while meeting their sustainability targets. We are committed to ensuring a sustainable business model for the future and this latest deal will improve the returns on investment across our portfolio, which can then be reinvested into the business.”
ABOUT AtlasEdge
AtlasEdge is a European edge data centre business with a mission to create Europe’s leading edge platform, delivering seamless, localised and ultra-low latency digital infrastructure to customers. Formed through a joint investment by Liberty Global, one of the world’s leading converged video, broadband and communications companies and DigitalBridge, a leading global investment firm dedicated to digital infrastructure, AtlasEdge already has an expanding portfolio of more than 100 data centres across the continent, providing proximity to the core network that is critical for the technology of tomorrow.
For more information, please visit www.atlasedge.com
ABOUT Colt DCS
Colt Data Centre Services provide true service and operational excellence in the sustainable design, build, delivery and operational management of hyperscale data centres across Europe and the APAC. We provide data centre solutions to hyperscale and large enterprise customers across 14 state of the art carrier neutral data centres spanning 8 cities. Our Hyperscale and colocation solutions allow our customers the freedom to plan effectively for the growth of their business, knowing that their data centre strategy is ready for the demands of tomorrow. We have over 25 years of experience in the industry, delivering on our vision of being the most trusted and customer centric data center operator in the market. We put environmental awareness at the heart of everything we do because we know it’s the right thing to do for our planet. That’s why we’re taking the ownership to reduce our environmental impact globally and make sustainability a key strategic driver. As part of our sustainability journey, alongside our sister company we are committed to achieving global net zero emissions for our own operations by 2030. https://www.coltdatacentres.net/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005298/en/
Contact information
AtlasEdge Corporate Communications:
Duncan White | duncan.white@atlasedge.com | +44 7970 974832
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
